End-of-day quote
Johannesburg S.E.
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
55.69
ZAR
|
+0.34%
|
|
+1.25%
|
-7.34%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
10,217
|
8,100
|
7,166
|
7,735
|
8,602
|
8,411
|
-
|
-
|
Enterprise Value (EV)
1 |
9,768
|
7,784
|
7,399
|
7,727
|
8,602
|
8,411
|
8,411
|
8,411
|
P/E ratio
|
14.4
x
|
12.1
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Yield
|
3.36%
|
2.08%
|
-
|
4.29%
|
4.44%
|
4.12%
|
4.38%
|
4.82%
|
Capitalization / Revenue
|
1.42
x
|
1.1
x
|
0.92
x
|
0.89
x
|
0.94
x
|
0.87
x
|
0.83
x
|
0.78
x
|
EV / Revenue
|
1.42
x
|
1.1
x
|
0.92
x
|
0.89
x
|
0.94
x
|
0.87
x
|
0.83
x
|
0.78
x
|
EV / EBITDA
|
9.72
x
|
7.49
x
|
6.86
x
|
6.21
x
|
6.45
x
|
5.97
x
|
5.62
x
|
5.14
x
|
EV / FCF
|
35,172,080
x
|
21,755,394
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
2.32
x
|
1.77
x
|
1.53
x
|
1.53
x
|
-
|
1.42
x
|
1.29
x
|
1.17
x
|
Nbr of stocks (in thousands)
|
171,422
|
168,759
|
161,759
|
155,759
|
152,796
|
151,026
|
-
|
-
|
Reference price
2 |
59.60
|
48.00
|
44.30
|
49.66
|
56.30
|
55.69
|
55.69
|
55.69
|
Announcement Date
|
8/27/19
|
8/26/20
|
8/25/21
|
8/24/22
|
8/22/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
7,175
|
7,347
|
7,777
|
8,706
|
9,132
|
9,618
|
10,191
|
10,815
|
EBITDA
1 |
1,051
|
1,082
|
1,045
|
1,245
|
1,334
|
1,409
|
1,497
|
1,635
|
EBIT
1 |
886.6
|
862.2
|
849.8
|
1,053
|
1,136
|
1,203
|
1,275
|
1,396
|
Operating Margin
|
12.36%
|
11.74%
|
10.93%
|
12.09%
|
12.43%
|
12.51%
|
12.51%
|
12.91%
|
Earnings before Tax (EBT)
1 |
969.6
|
930
|
905.9
|
1,102
|
1,205
|
1,277
|
1,358
|
1,494
|
Net income
|
688
|
682.2
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
9.59%
|
9.29%
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
4.138
|
3.980
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
290.5
|
372.3
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
4.05%
|
5.07%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
27.64%
|
34.41%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
42.22%
|
54.58%
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
2.000
|
1.000
|
-
|
2.130
|
2.500
|
2.296
|
2.441
|
2.686
|
Announcement Date
|
8/27/19
|
8/26/20
|
8/25/21
|
8/24/22
|
8/22/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
233
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
448
|
317
|
-
|
7.74
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
0.2234
x
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
290
|
372
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
16.8%
|
15.3%
|
14.3%
|
16.1%
|
16.9%
|
15.8%
|
15.8%
|
15.7%
|
ROA (Net income/ Total Assets)
|
11%
|
10.1%
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
6,261
|
6,774
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
1 |
25.70
|
27.10
|
28.90
|
32.40
|
-
|
39.10
|
43.20
|
47.70
|
Cash Flow per Share
1 |
3.040
|
3.090
|
1.980
|
3.990
|
-
|
6.210
|
6.980
|
7.660
|
Capex
2 |
215
|
154
|
112
|
120
|
-
|
289
|
306
|
324
|
Capex / Sales
|
3%
|
2.09%
|
1.44%
|
1.38%
|
-
|
3%
|
3%
|
3%
|
Announcement Date
|
8/27/19
|
8/26/20
|
8/25/21
|
8/24/22
|
8/22/23
|
-
|
-
|
-
|
Last Close Price
55.69
ZAR Average target price
56
ZAR Spread / Average Target +0.56% Consensus |
1st Jan change
|
Capi.
|
---|
| -7.34% | 447M | | +19.62% | 43.34B | | +20.44% | 21.96B | | +10.86% | 14.09B | | +13.07% | 13.64B | | +37.46% | 11.43B | | -8.59% | 6.86B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +8.46% | 5.22B |
Generic Pharmaceuticals
|